Significant Research

News Articles for Significant Research top ^
Statistically significant mean placebo-adjusted reduction of triglycerides of 36.4% at 1 gram and 38.6% at 2 gram daily doses of CaPre® Statistically significant reduction of 5.3% in non-HDL-C using 2 grams of CaPre® daily (considered the most accurate risk marker for cardiovascular disease) No increases in LDL-C (bad cholesterol) and slight increases in HDL-C (good cholesterol) Clinically meaningful mean placebo-adjusted reduction in VLDL-C of 10.9% and 13.5% at 1 gram and 2 gram daily doses CaPre®, respectively (VLDL-C is considered a highly significant predictor of cardiovascular disease) Statistically significant dose dependent improvement in Omega-3 Index (a risk factor for coronary heart disease) CaPre® shown to be safe, well tolerated and effective LAVAL, Quebec, Sept.
Sign-up for Acasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C investment picks
Data From Phase 3 RUTHERFORD-2 Study Show Evolocumab Significantly Reduced Mean LDL-C by 59-66 Percent Compared to Placebo in Patients With Heterozygous Familial Hypercholesterolemia Phase 3 TESLA Data Show Evolocumab Significantly Reduced LDL-C by 31 Percent Compared to Placebo in Patients With Homozygous Familial Hypercholesterolemia THOUSAND OAKS, Calif.
Sign-up for The Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol investment picks
CIT Group Inc. (NYSE:CIT) , a leading provider of commercial lending and leasing services, today announced that it provided a senior secured credit facility to support Rosser Capital Partners’ significant investment in PetPeople, a specialty retail pet supply store that focuses on high quality, natural pet food.
Sign-up for CIT Provides Financing for Rosser Capital Partners’ Significant Investment in PetPeople investment picks
Shareholder rights law firm Johnson & Weaver, LLP reminds investors of the September 16, 2014 lead plaintiff deadline in a securities class action lawsuit filed by the firm against Prosensa Holding N.V. (NASDAQ:RNA). The class action lawsuit was filed in the United States District Court for the Southern District of New York on behalf of the class (the “Class”). Those purchasers of the ordinary common shares of Prosensa pursuant and/or traceable to the Company's initial public offering (“IPO”) on or about June 28, 2013 and suffered significant losses are encouraged to contact Johnson & Weaver regarding your legal rights.
Sign-up for PROSENSA HOLDING N.V. SHAREHOLDER ALERT: Johnson & Weaver, LLP Reminds Investors of Upcoming September 16, 2014 Deadline; Encourages Investors with Significant Losses to Contact the Firm investment picks
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today presented data from a Phase 1/2a study of GEN-003, the Company’s investigational immunotherapy against HSV-2, demonstrating that the immunotherapy elicited T cell, IgG and neutralizing antibody responses that remained significantly above baseline for 12 months after treatment.
Sign-up for Genocea HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses in Vaccinated Subjects investment picks
From the South American Hotel Investment Conference in Quito, Starwood Hotels & Resorts Worldwide, Inc. (NYSE:HOT) announced that it is continuing its aggressive growth strategy in Latin America with significant gains across its Specialty Select Brands’ (SSB), Four Points by Sheraton and Aloft.
Sign-up for Starwood Hotels & Resorts Continues to Expand Latin American Portfolio, Making Significant Gains in the Specialty Select Segment investment picks
Docupace Technologies (Docupace), the premier provider of secure and compliant electronic processing technology for financial institutions and the wealth management industry announced today that RCS Capital Corporation (NYSE: RCAP) will help drive Docupace’s next stage growth plans with a significant investment in the company.
Sign-up for Docupace Technologies Announces Significant Investment from RCS Capital investment picks
SAS reports significant exploration results from the Holt property Canada NewsWire 9.97 g/t Au over 11.2 metres (9.28 g/t Au cut) including 19.45 g/t Au over 4.6 metres (17.77 g/t Au cut) TORONTO , Oct.
Sign-up for SAS reports significant exploration results from the Holt property investment picks
Freegold Defines Significant Geophysical and Geochemical Targets at Shorty Creek Canada NewsWire VANCOUVER , Sept.
Sign-up for Freegold Defines Significant Geophysical and Geochemical Targets at Shorty Creek investment picks
CANTON, Ga., Sept.
Sign-up for Blue Water Finalizes Second Significant Equity Investment investment picks
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced results of a pre-specified secondary analysis of the Eliquis Phase 3 AMPLIFY-EXT trial (A pixaban after the initial M anagement of P u L monary embol I sm and deep vein thrombosis with F irst-line therap Y - EXT ended Treatment). The analysis evaluated clinical and demographic predictors of all-cause hospitalization in patients with VTE, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Results from this analysis demonstrated that during the 12-month extended treatment of VTE, Eliquis significantly reduced the risk of hospitalization versus placebo.
Sign-up for Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE) investment picks
Diversity in the U.S. power supply—the most cost-effective means of managing the inherent risks in fuel costs and technology performance in generating power—could be dramatically reduced in coming decades, says a new study by IHS (NYSE: IHS), the leading global source of critical information and insight.
Sign-up for IHS Study: Diversity of United States Power Supply Could be Significantly Reduced in Coming Decades investment picks
A study by EMA Research found that organizations using security analytics and threat analytics are nearly two times as confident of detecting security issues and 90 percent report reduced false alerts compared to those not using these tools.
Sign-up for Study Finds Security Analytics Significantly Decrease False Alerts investment picks
- Judicial states account for 42 percent of active mortgages, yet more than 70 percent of foreclosure inventory - Foreclosure inventory in judicial states is 3.5 times that of non-judicial - HAMP modifications performing better than proprietary counterparts - Short sales decline to just under 34 percent of all distressed transactions JACKSONVILLE, Fla.
Sign-up for Black Knight's June Mortgage Data: Foreclosure Inventory Significantly Higher in Judicial States; Short Sale Percentages, Discounts Decreasing investment picks
2014/7/30 NEW YORK, NY --
Sign-up for Video Resolution Significantly Affects Digital Ad Engagement: Study investment picks
CyberOptics Corporation (Nasdaq: CYBE) today reported significantly improved operating results for the second quarter of 2014.
Sign-up for CyberOptics Reports Significantly Improved Second Quarter Operating Results investment picks
NEW YORK , July 28, 2014 /PRNewswire/ -- Tripp Levy PLLC, a leading national securities law firm, announces that it is investigating potential securities fraud claims against Swift Transportation Co.
Sign-up for Swift Transportation - National Securities Law Firm Encourages Shareholders With Significant Losses To Contact Law Firm investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar

Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Significant Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Significant Losses  |  Next: Significant Revenues